Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled amikacin for prevention of ventilator-associated pneumonia
2016-001054-17Phase 3Completed
- Sponsor
- CHRU Tours
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing Inhaled amikacin with Placebo (2 arms). Primary endpoint: Incidence of first ventilator-associated pneumonia episode. Started May 2017; status: completed.
02
Drugs
amikacin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2016-001054-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001054-17.